Ranibizumab for Neovascular Age-Related Macular Degeneration

Top Cited Papers

5 October 2006

journal article
research article
Published by Massachusetts Medical Society in New England Journal of Medicine

Vol. 355 (14) , 1419-1431
https://doi.org/10.1056/nejmoa054481

Abstract

Ranibizumab — a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A — has been evaluated for the treatment of neovascular age-related macular degeneration.

Keywords

This publication has 20 references indexed in Scilit:

GUIDELINES FOR USING VERTEPORFIN (VISUDYNE) IN PHOTODYNAMIC THERAPY FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION AND OTHER CAUSES: UPDATE
Retina, 2005
Pegaptanib for Neovascular Age-Related Macular Degeneration
New England Journal of Medicine, 2004
Racial Variations in Causes of Vision Loss in Nursing Homes
Archives of Ophthalmology (1950), 2004
Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .
JAMA, 2004
Photodynamic Therapy of Subfoveal Choroidal Neovascularization With Verteporfin
Archives of Ophthalmology (1950), 2003
Vascular Endothelial Growth Factor Family and Receptor Expression in Human Choroidal Neovascular Membranes
Microvascular Research, 2002
Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2
American Journal of Ophthalmology, 2001
Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-related Macular Degeneration With Verteporfin
Archives of Ophthalmology (1950), 1999
Increased expression of angiogenic growth factors in age-related maculopathy
British Journal of Ophthalmology, 1997
Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Are Present in Epiretinal and Choroidal Neovascular Membranes
American Journal of Ophthalmology, 1996